Commercialization Strategies In Global Biosimilars Industry

Frost & Sullivan recently invited industry leaders in biopharmaceutical manufacturing to participate in a new and unique thought leadership forum, our Executive Think Tank Dinner. This forum brought together leading minds in manufacturing to discuss key trends, challenges and success factors in global biosimilars industry.

Nitin Naik, with Frost & Sullivan, opened the discussion by noting that Frost & Sullivan analyst team put a stake in the ground around mapping commercialization challenges back in 2015. He went on to explain key commercialization considerations by offering the following Frost & Sullivan definition:

“A biosimilar is a biologic that is “highly similar” to an approved biologic (or reference product) that is already being used to treat patients. The goal of a biosimilar development program is not to re-establish the safety and efficacy of the product, but rather to demonstrate that the biologic product is biosimilar to the reference product. It is generally understood that there are acceptable variabilities between the biosimilar and the branded reference product, and an approved biosimilar will have no clinically meaningful differences from there ference product in terms of efficacy and safety.

The discussion began with participants sharing perspectives on key growth drivers and regions that present greatest potential.